We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Humana (HUM) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
Read MoreHide Full Article
For the quarter ended March 2024, Humana (HUM - Free Report) reported revenue of $29.33 billion, up 9.7% over the same period last year. EPS came in at $7.23, compared to $9.38 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $28.6 billion, representing a surprise of +2.55%. The company delivered an EPS surprise of +20.10%, with the consensus EPS estimate being $6.02.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Humana performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Benefits Expense Ratio - Consolidated: 88.9% versus the six-analyst average estimate of 88.5%.
Medical Membership - Total Medicare: 8,447.4 thousand compared to the 8,493.34 thousand average estimate based on three analysts.
Medical Membership- Medicaid and other: 1,261.4 thousand versus 1,267.5 thousand estimated by three analysts on average.
Medical Membership - Group Medicare Advantage: 551.5 thousand versus the three-analyst average estimate of 546.2 thousand.
Revenues- Investment income (loss): $288 million versus $298.90 million estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +49.2% change.
Revenues- Premiums: $28.26 billion compared to the $27.03 billion average estimate based on six analysts. The reported number represents a change of +10.6% year over year.
Revenues- Services: $1.06 billion versus the six-analyst average estimate of $942.23 million.
Revenue- CenterWell: $4.82 billion versus the five-analyst average estimate of $4.71 billion.
Revenues- Consolidated- Premiums- Specialty benefits: $239 million versus the four-analyst average estimate of $255.13 million.
Revenue- Insurance: $28.70 billion versus the four-analyst average estimate of $27.78 billion.
Insurance segment- Services revenue- Military and other: $251 million compared to the $186.79 million average estimate based on four analysts.
Insurance segment - Intersegment revenues- Services: $1 million compared to the $5.75 million average estimate based on four analysts.
Shares of Humana have returned -5.9% over the past month versus the Zacks S&P 500 composite's -3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
(We are reissuing this article to correct a mistake. The original article, issued earlier today, should no longer be relied upon.)
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Humana (HUM) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
For the quarter ended March 2024, Humana (HUM - Free Report) reported revenue of $29.33 billion, up 9.7% over the same period last year. EPS came in at $7.23, compared to $9.38 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $28.6 billion, representing a surprise of +2.55%. The company delivered an EPS surprise of +20.10%, with the consensus EPS estimate being $6.02.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Humana performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
View all Key Company Metrics for Humana here>>>
Shares of Humana have returned -5.9% over the past month versus the Zacks S&P 500 composite's -3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
(We are reissuing this article to correct a mistake. The original article, issued earlier today, should no longer be relied upon.)